Pharsight

Vitekta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(2 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(2 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(2 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(2 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(2 years from now)

Vitekta is owned by Gilead Sciences Inc.

Vitekta contains Elvitegravir.

Vitekta has a total of 6 drug patents out of which 0 drug patents have expired.

Vitekta was authorised for market use on 24 September, 2014.

Vitekta is available in tablet;oral dosage forms.

Vitekta can be used as treatment of hiv infection.

Drug patent challenges can be filed against Vitekta from 27 August, 2016.

The generics of Vitekta are possible to be released after 26 April, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017
New Product(NP) Sep 24, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ELVITEGRAVIR ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 24 September, 2014

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage

VITEKTA family patents

Family Patents